Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211672 | 0.78 | MAOB (0.31) | MAOB | |
| SCHEMBL13197707 | 0.73 | HPRT1 (0.39) | MPOXDHGPR84PDE7APDE7B | |
| SCHEMBL26692251 | 0.71 | DAO (0.45) | MAOB | |
| SCHEMBL12402889 | 0.70 | HPRT1 (0.38) | GPR84PDE7APDE7BCES2CES1 | |
| SCHEMBL25362170 | 0.69 | DAO (0.48) | MPOXDHGPR84 | |
| SCHEMBL24289455 | 0.67 | DAO (0.46) | — | |
| SCHEMBL16471452 | 0.65 | — | — | |
| SCHEMBL8442265 | 0.65 | GPR84 (0.30) | GPR84PDE7APDE7B | |
| SCHEMBL15728304 | 0.65 | GPR84 (0.33) | GPR84PDE7APDE7BCES2CES1 | |
| SCHEMBL4930057 | 0.63 | GRIN2D (0.44) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296985-B1 | HETEROPOLYCYCLIC INHIBITORS | QUADRA LOGIC TECH INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| US-20030144294-A1 | Heteropolycyclic inhibitors of protein kinases | QLT INC. (CA) | 2003-07-31 | — | — | US | disclosed |
| EP-1296985-A2 | HETEROPOLYCYCLIC INHIBITORS | Kinetek Pharmaceuticals, Inc. (CA) | 2003-04-02 | — | — | EP | disclosed |
| US-6514972-B2 | Antiproliferative agents | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-02-04 | — | — | US | disclosed |
| US-20020035251-A1 | Heteropolycyclic inhibitors of protein kinases | KINETEK PHARMACEUTICALS, INC. (CA) | 2002-03-21 | — | — | US | disclosed |
| WO-2002002562-A2 | HETEROPOLYCYCLIC INHIBITORS | KINETEK PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035251-A1 | Heteropolycyclic inhibitors of protein kinases | DSTYK, PRKCZ, CSNK1A1L | MPO 4347/4885XDH 1839/4885MAOB 3184/4885 |
| US-20030144294-A1 | Heteropolycyclic inhibitors of protein kinases | DSTYK, PRKCZ, CSNK1A1L | MPO 4347/4885XDH 1839/4885MAOB 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.